Cargando…

Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells

Downregulation of MHC class I (MHCI) molecules on tumor cells is recognized as a resistance mechanism of cancer immunotherapy. Given that MHCI molecules are potent regulators of immune responses, we postulated that the expression of MHCI by tumor cells influences systemic immune responses. According...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neo, Shi Yong, Jing, Xu, Tong, Le, Tong, Dongmei, Gao, Juan, Chen, Ziqing, De Los Santos, Mireia Cruz, Burduli, Nutsa, De Souza Ferreira, Sabrina, Wagner, Arnika Kathleen, Alici, Evren, Rolny, Charlotte, Cao, Yihai, Lundqvist, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608525/ https://www.ncbi.nlm.nih.gov/pubmed/36283735 http://dx.doi.org/10.1136/jitc-2022-005308

Ejemplares similares

CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor
por: Zilio, Serena, et al.
Publicado: (2022)

Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells
por: Chen, Ziqing, et al.
Publicado: (2021)

Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744
por: Friedrich, Michael, et al.
Publicado: (2020)

N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor
por: Lou, Chao, et al.
Publicado: (2022)

Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
por: Zhang, Biying, et al.
Publicado: (2023)

Renal cell carcinoma escapes NK cell‐mediated immune surveillance through the downregulation of DNAM‐1
por: Tong, Le, et al.
Publicado: (2023)

Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation
por: Deng, Guoliang, et al.
Publicado: (2022)

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023)

Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms
por: Neuwelt, Alexander J, et al.
Publicado: (2020)

IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts
por: Chen, Lujun, et al.
Publicado: (2022)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells
por: Landolina, Nadine, et al.
Publicado: (2022)

Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch
por: Cornel, Annelisa M, et al.
Publicado: (2022)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
por: Bernard, Pierre-Louis, et al.
Publicado: (2022)

Engineered NK Cells Against Cancer and Their Potential Applications Beyond
por: Karvouni, Maria, et al.
Publicado: (2022)

PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling
por: Raja, Remya, et al.
Publicado: (2022)

2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis
por: Pan, Banglun, et al.
Publicado: (2023)

Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(−) subset
por: Veneziani, Irene, et al.
Publicado: (2022)

CD25(bright) NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression
por: Chen, Ziqing, et al.
Publicado: (2023)

IFN-γ treatment protocol for MHC-I(lo)/PD-L1(+) pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential
por: Stifter, Katja, et al.
Publicado: (2020)

Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation
por: Sun, Yu, et al.
Publicado: (2023)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
por: Fitzgerald, Allison A, et al.
Publicado: (2021)

Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy
por: Peng, Peng, et al.
Publicado: (2022)

Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition
por: Sottile, Rosa, et al.
Publicado: (2019)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

Activated but impaired IFN-γ production of mucosal-associated invariant T cells in patients with hepatocellular carcinoma
por: Huang, Wenyong, et al.
Publicado: (2021)

Design, synthesis and immunological evaluation of self-assembled antigenic peptides from dual-antigen targets: a broad-spectrum candidate for an effective antibreast cancer therapy
por: Shi, Wei, et al.
Publicado: (2021)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
por: Bao, Xuanwen, et al.
Publicado: (2020)

Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators
por: Hou, Jiakai, et al.
Publicado: (2021)

Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization
por: Sheng, Dandan, et al.
Publicado: (2022)

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2021)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity
por: Ye, Jun, et al.
Publicado: (2021)

Genome-scale CRISPR–Cas9 screen reveals novel regulators of B7-H3 in tumor cells
por: Zhao, Shasha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_053qm9obpq9beq4ih955ua1k2j